{"name":"HiberCell, Inc.","slug":"hibercell-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQTFBSQXBOMW5PeVhuOHVaLUYzeUswZ3B1QXFwNEdWU28xc0ktSndQWnE3aFZKa2trTDBGMzFLVGdfdndnOGJHSWJXUldEeE5Rbk04Q0taY0hjY1pzaGFCS041Y3J3elBLa0RNeTgzNV9KSFlvNTRLUUcyeDdyVFJDVVpuTDNod3VqdHJDN0JQdUY?oc=5","date":"2026-04-06","type":"pipeline","source":"openPR.com","summary":"Triple Negative Breast Cancer Pipeline 2026: MOA, ROA, - openPR.com","headline":"Triple Negative Breast Cancer Pipeline 2026: MOA, ROA,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPUXUtVVNKZ2JudHZyeUJlcTRzMy1SbWpVX3lxNjR5ZnIwOHlWazVydFJ6dDd0bUUzYTJXQ2xVblVLZ2Z0ZEpveW5fOE1pT21IMXZKMzc5c1lLNTF2VEt0Z1U0WWNnRXdjZC1ydXJhV0ZVV2lpSE1VYmFVMlRLXzJxUDE2TzFoczFyczg4am5GSExjc1B6LWhMbUhuU3ktTkZpZDRzY3FvZlhnQ0hJRmJvbXpXak8xTXBBRkQ3SXBGZHV4aW5MMkpMc3BEeWxEY19OS2VhSmUxb25hY2ZoVHd2SlNjLURqeWoxOTd1WTM3TmZuWkxoNDRESlhzbmUtSGw5NE9CVGhGaHo?oc=5","date":"2026-02-18","type":"trial","source":"PR Newswire","summary":"AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN Study - PR Newswire","headline":"AVEO Oncology, an LG Chem company, Announces Completion of the First Interim Analysis in the Global Phase 3 FIERCE-HN St","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxOcUdCOUNDUzI1VlJOMGF2YmJJYW5jMjFYQlczenJRQVM3b0VTUTZvYXV2VE9FYTJSZkU2VUpsLUh1VHJST3JlVUNNOS1rbWJNRGxMYmxCSzM0QW1tblRSWk1ib3ktVzVjLWFNN2VxelBwX3pLbnBSWG45UnNjcmE5akJzYlQ5NDRFNlRjX3ZKazItOGV4RVZsc2ZIY3pOQ1ppLTV2UWZjRlBkdlRnOEgtODRvTThUYjVfV1FzaVdJTnFqOVdNdlU5Ykt4bXBfVjRhU2JMT1lzcnRGckFTYjhPODVfWTlOZ1dqd1NvM1UxWTk2Y2k2cnBmaWZYaE5KZWs?oc=5","date":"2026-01-14","type":"trial","source":"PR Newswire","summary":"AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab - PR Newswire","headline":"AVEO Oncology, an LG Chem company, Announces First Patient Dosed in Front-Line AML Combination Study of Ficlatuzumab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNWk5QY1A2c0Ryc0dobWlGYk1rdUZpQnVNeXQ4NWh2RENmMXh2UjNzcXJXU1piVEstcElUSk82Q2ZXUFhDaHo4SE1uamJBdDJ5LWFoTHZ2UUNTdFB0b3ZuNzUxaXlyMVU3SnFobTdlOFBwZzRrTVlJVHZVV2M1UTZSWThfMngtS1pFRVJr?oc=5","date":"2025-12-04","type":"trial","source":"Yahoo Finance","summary":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Yahoo Finance","headline":"Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Dom","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNMFQ3c09BMWZRVjlRMlAwRThjZ2tuRDVXQ3FpcWZpZTgzbVJVTTlDVWVtZmRGX2xwVjkxV3ZoUEFwU29NN3V5MGlfdGtPS05QTWdLZjg4SERaNXl1NWh5Mm9RMnU5TTV2dUhYSVgxU2xPT3B1R1NCNVlmYks5elNTVE9VUUpmODNjaVBfY25NbXQ1WkFyN29tcndYQ2k4c1FPU2FiZzEzVlpyby1JZnNSZXZQdDhXZFRJWHVoLUFYMDhNc0dpal9uMA?oc=5","date":"2025-11-05","type":"deal","source":"BioPharma APAC","summary":"AVEO and HiberCell Partner to Develop First-in-Human PERK Inhibitor for Kidney Cancer - BioPharma APAC","headline":"AVEO and HiberCell Partner to Develop First-in-Human PERK Inhibitor for Kidney Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBGYjI3UXp3MnhDa1ZYWnZnU3U4UnljX25YU0RiREhuOVctRk1uTEVORnJlZHZpamp6Y29JRDRLbEdfYWJGU2FMWDdnMzhfTHZlbWpub3NrdVEwU3RNRjZjNTJJNXlzdndQWFZKeS130gFyQVVfeXFMTkRVbTFHWXd1NXpybVZVckYxWG5RSE04TWJPRy1MYzlPM2s4MGF5UzlSMnZmWWZRYXVIQzdROGpJRnlhMGJySkhjNnk0ejVJRkhuM2U5bUpXMUJqQ2pTUlI3U1kxZ1daUThLdmd3WS1PYkh3?oc=5","date":"2025-11-05","type":"deal","source":"koreabiomed.com","summary":"LG Chem strengthens oncology with HiberCell partnership for next-gen kidney cancer drug - koreabiomed.com","headline":"LG Chem strengthens oncology with HiberCell partnership for next-gen kidney cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxOX3VyQ2szQ3RYck5GSTZuanpKZjBMS2pUZXJUNWxPcTJtSXUzeVZfTTN1cnE2T08tZGlKcUpUdU50dWJmNFFKQW1aQkhuN0V0a2FjdEpDc3pLUDg5amtMTk1JdEJjMXlBdnlZSzhjYmlXbW84N21rSFVmOXkwdG9CR2NVVVVyVEpMQi1pWWVvNl9rQTBkMmJTV1ZSTmxJc01pdXFQVngtWWlTdkpucVFRTE8tRF9RQW05dktUY2RFTGtVTjJHd0xIb1Nqb19sdC1SZ2pOUmEzNnE4cmFGTEwzeDJVTl9IaEl1RjljdkxxU0gybklWVG96U3hfX09Hd0ZTVkFhamtoQXpLSGt6MkJXZ19sajQ3dw?oc=5","date":"2025-11-04","type":"pipeline","source":"PR Newswire","summary":"AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-Human Compound - PR Newswire","headline":"AVEO Oncology, an LG Chem company, and HiberCell Enter Into an Exclusive Development and Option Agreement for First-in-H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTDg1bkZCUXRFcWdjM0NUYWhiWW1GeHo0WVlINGtSTGh3RXRsTlNvRzdlS3ZWeW8wU0RvcUZ0NENFSHpLOERqWV9UdllFcWp4V3drWGVZbkU3TmJfYnVHb0lVUXdwVnVMUVpaam9jeXFLZkIydVlXVGluU2cyUTNCaWlaVDRPelE4dWlMYVV6cVBVRk5MQ0pRQzdKRUtMUzBDc3BpRnB1OTBtVEl6dGJQbkYxTF9yYklIOFF0V191anVvNEk?oc=5","date":"2025-03-30","type":"pipeline","source":"The Times","summary":"Prostitution scandal hits taxpayer-backed Irish genome venture - The Times","headline":"Prostitution scandal hits taxpayer-backed Irish genome venture","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBjZU1rcGN5eXN1d2wwYlZYOWN1U1o5UVJucDdsMHBKNlUwOWY4ZWJjTFV4NzN3ZFlkTllHdFkzMVNFN0hEWXVRUUZId1VDQjdRaXNBS0NHTHg0cmVIN2ZjQjJrQV9jcVM0aVVMNDdjNndBXy1EVzVoWndB?oc=5","date":"2024-11-15","type":"trial","source":"Oncology Pipeline","summary":"The markets stress over Nuvectis | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"The markets stress over Nuvectis | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNYlQxMmZLZHd6eHBzejNlTVBSM0xONk5qQjZCREg5Zkt1WnBQVzNZUXUyVm9TLWpOZzlBb2pfSXRnT2p2aGFWZ0ZTc1VLMjF6TVBWc0FRZnpzWDdEM2hTWnUyU3p3aEduLVd3UVoyRGJHNWdNLWhOVnV4MjZnQ2s4SlVKWGtqUUUzNnJIeU82NEtOalh2MVRMdThTZG5nRkE?oc=5","date":"2024-11-01","type":"regulatory","source":"Oncology News Central","summary":"Oncology Drugs Fast-Tracked by the FDA in October 2024 - Oncology News Central","headline":"Oncology Drugs Fast-Tracked by the FDA in October 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQbjN4Rm9ZUmhTcGE4aHFxbWFINnZLRkt4ZjdiSkdNLS1LTWZjUTZBV3R4Zm9YR0xWTjktTDBNQk1hV2kyUExmamJsTjNELVZSSnl3dnlTNjRiWGU2M0VZRDB6ODhyTS0zamdOUWlCVXZRQl9oZkZtM1ZkUG9oNTdBa1dqRFhyYktYcGRhYmpTTXNmR0pFMmZoTVQwejlBN3NCbXU0?oc=5","date":"2021-09-30","type":"pipeline","source":"citybiz","summary":"HiberCell Appoints Jonathan Lanfear as Chief Operating Officer - citybiz","headline":"HiberCell Appoints Jonathan Lanfear as Chief Operating Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPa3phSUc0dWFmWkpPeVV4c2xPRlV1bUFNcGZYT1lXS2ZqSERGempfZ0RaRkF5T3hhejlLeGwyQXNMMmR1ejVpQUE5RmxwVkFKT1ZfSTJhNUVXNDVJblJvQUtiZDE0X0ZWYXIxTU1paGJzS1ZZcnZwNjFVQnZtY2ZZcjZrZmZlRjJPa2tERGhjU0ZUOFNIZmxKWUpfQzIxc2FjYTVqMmZWSWk5a2c?oc=5","date":"2021-08-16","type":"deal","source":"MedCity News","summary":"HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie - MedCity News","headline":"HiberCell’s Genuity buyout brings $100M, plus alliances with Ionis and AbbVie","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}